Clinical measures, biomarker prevalence and model definition
Measure | Parent cohort | Metabolomics subcohort | ||
Controls n=127 | WTC-LI n=96 | Controls n=15 | WTC-LI n=15 | |
PFT at SPE | ||||
FEV1, % Pred*† | 93 (85–99) | 72 (66–75) | 92 (90–98) | 73 (70–75) |
FVC% Pred*† | 96 (89–103) | 79 (72–85) | 97 (95–100) | 78 (75–88) |
FEV1/FVC*† | 76 (73–80) | 72 (65–77) | 75 (71–82) | 71 (64–76) |
BMI (kg/m2) | ||||
MMTP entry*†‡ | 28 (26–30) | 29 (27–31) | 26 (25–27) | 29 (26–31) |
SPE*†‡ | 29 (27–31) | 30 (28–34) | 26 (24–28) | 30 (28–31) |
Age on 9/11 (years) | 41 (37–45) | 40 (36–45) | 42 (38–46) | 39 (37–46) |
Exposure N (%) | ||||
Low* | 13 (10%) | 21 (22%) | 1 (7%) | 4 (27%) |
Intermediate* | 85 (67%) | 46 (48%) | 11 (73%) | 8 (53%) |
High* | 29 (23%) | 29 (30%) | 3 (20%) | 3 (20%) |
Duration (months)* | 3 (1–5) | 1 (1–4) | 2 (1–5) | 3 (1–5) |
Lipids (mg/dL) | ||||
Triglycerides | 164 (98–238) | 157 (107–243) | 126 (99–237) | 133 (110–201) |
HDL§ | 47 (40–55) | 43 (38–54) | 48 (45–57) | 42 (3 5–57) |
LDL¶ | 131 (104–157) | 131 (108–153) | 134 (100–144) | 147 (115–162) |
Heart rate*†‡§ (beats/min) | 72 (66–76) | 74 (69–80) | 66 (64–70) | 75 (68–79) |
BP (mm Hg) | ||||
Systolic†‡§ | 114 (108–124) | 120 (110–128) | 110 (100–112) | 119 (108–129) |
Diastolic‡§ | 70 (70–80) | 75 (70–81) | 70 (60– 72) | 71 (66–80) |
Values in median (IQR) or N (%) as indicated. Significant by Mann-Whitney U or χ2 between:
*127 vs 96.
†15 vs 15.
‡ Controls 127 vs 15.
§Data available for 14 subcohort WTC-LI cases.
¶Data available for 13 subcohort WTC-LI cases; all comparisons between cases 96 vs 15 were insignificant.
BMI, body mass index; BP, blood pressure; FEV 1,%, pred forced expiratory volume in 1 s per cent predicted of normal; FVC %, pred forced vital capacity per cent predicted of normal; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MMTP, medical monitoring and treatment programme; PFT, Pulmonary Function Test; SPE, subspecialty pulmonary examination; WTC-LI, World Trade Center Lung Injury.